Skip to main content
Book Chapter

Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations

  • Källén B
Springer International Publishing, (2019), 41-45
DOI: 10.1007/978-3-030-17898-7_5
N/ACitations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Relatively little data are available on the use of modern anti-obesity drugs in early pregnancy. There seems to be no effect of the use of orlistat but an indicated doubling of malformation risk after sibutramine which should be avoided in early pregnancy.

Cite

CITATION STYLE

APA

Källén, B. (2019). Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations. In Maternal Drug Use and Infant Congenital Malformations (pp. 41–45). Springer International Publishing. https://doi.org/10.1007/978-3-030-17898-7_5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free